AI-DRIVEN DRUG GENERATION

Powered By Award-Winning AI Drug Discovery Platform

We aim to advance current state-of-the-art AI drug discovery technologies and transform high-cost, low-efficiency drug discovery practices into rapid, efficient discovery, ultimately leading to high success rates in the clinical phase.

Our award-winning AI drug discovery platform enables the direct discovery of high potency drugs that induce desired cellular-level activity with minimal off-target effects and toxicity.

AIGEN Sciences will revolutionize AI-based drug discovery.

Achievements

Awards

Research Collaboration

Note: Prior to the establishment of AIGEN Sciences Inc.(Apr 2021), the accomplishments were made through KU (Korea Univ) DMIS Lab. AIGEN Sciences Inc. is a spin-off of KU DMIS. 

History

2023 

Jan.

Research Collaboration with YUHAN
: Anti-cancer drugs mechanism identification

2022 

Nov.

Research Collaboration with NOVELTY NOBILITY Inc.
: Novel ADC payload development 

2022 

Oct.

Raised KRW 4.2B in pre-series A funding 

2022 

May.

MOU with K-Medi HUB: Collaboration for AI-based innovative drug development 

2022 

Feb.

Research Collaboration with Incurix: Transcription factor inhibitor development

2022 

Jan.

Sponsored Research with Avelos Therapeutics: Anti-cancer drug discovery 

2021 

Nov.

Government Research Project with LMITO Therapeutics

Granted by Korea Drug Development Fund (KDDF), a government-initiated drug development program.

2021 

Nov.

Winning 1st and 3rd place: BioCreative VII Challenge
Collaboration with KU and AstraZeneca

Outperforming ETH, NVIDIA

2021 

Apr.

Reseach Collaboration with LMITO Therapeutics : Autoimmune diseases

Apr.

AIGEN Sciences Established

2020 

Oct.

Winning 1st place: BioASQ Biomedical Semantic Indexing and Question Answering 

Outperforming UCSD, UMass-Chan Zuckerberg Initiative

Jun.

Joint Research with Global Big Pharma "A" : AI for Biomedical Natural Language Processing

Apr.

Research Collaboration with Donga -ST : Rare neurovascular diseases therapeutics

Feb.

Research Collaboration with LMITO Therapeutics : Neurodegenerative diseases therapeutics 

2019

Nov.

Research Collaboration with Crystal Genomics : Immunotherapeutics combination 

Nov.

Winning 1st place: IDG-DREAM Drug-Kinase Binding Prediction Challenge

Joint 1st place with UIUC, UNC Chapel Hill

Sep.

Winning 1st place: BioASQ Biomedical Semantic Indexing and Question Answering 

Outperforming Google (2nd place)

2018

Dec.

Winning 1st place: Multi-targeting Drug DREAM Challenge 

Outperforming Janssen Pharmaceuticals (4th place)

2017

Nov.

Winning 1st place: NCI-CPTAC DREAM Proteogenomics Challenge 

Outperforming UCLA (2nd place) and MD Anderson (16th place) 

2016

Oct.

Winning 2nd place: Disease Module Identification DREAM Challenge

Outperforming Stanford (11th place) and Yale (18th place)

Mar.

Winning 2nd place: AstraZeneca-Sanger Drug Combination Prediction Challenge 

Outperforming Stanford (6th place) and MIT (11th place)